
Opinion|Videos|June 23, 2025
Overcoming Challenges for Wider Adoption of TLX250
Panelists discuss how molecular imaging might help with complex renal mass decision-making, potentially identifying aggressive clear cell biology that would warrant radical rather than partial nephrectomy, though anatomical details would still require conventional imaging.
Advertisement
Episodes in this series

Complex Renal Masses and Molecular Imaging
Main Discussion Topics:
- Challenges of managing anatomically complex renal masses
- Potential for molecular imaging to influence nephron-sparing decisions
- Tumors with aggressive biology may warrant radical nephrectomy, whereas those with indolent biology may be candidates for partial nephrectomy.
- Limitations in anatomic resolution compared with MRI
Key Points for Physicians:
- Molecular characteristics may influence decisions regarding partial vs radical nephrectomy.
- Aggressive biology might favor radical approach, even when partial is technically feasible.
- Indolent biology might support nephron sparing, even in challenging cases.
- Molecular imaging should complement rather than replace high-resolution anatomic imaging.
Notable Insights:
Molecular imaging provides biological rather than anatomic information and should be used in conjunction with conventional imaging for optimal decision-making.
Clinical Significance:
Integrating molecular and anatomic imaging could lead to more personalized surgical approaches based on both technical feasibility and biological risk.
Advertisement
Related to this article

Interim phase 3 data show a 58% reduction in the risk of metastasis or death with the addition of darolutamide to ADT + radiation.

Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.

Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.

The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.

At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.

The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.

Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Advertisement
Advertisement
Trending on Urology Times
1
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
2
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
3
In situ immunotherapy shows encouraging survival findings in prostate cancer
4
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
5

